Rhonda D. Cardin
Rhonda D. Cardin received her A.B. degree in Biology and Psychology in 1983 from Washington University in St. Louis, and in 1984, began her Ph.D. degree studies at Tulane University in New Orleans. In 1989, Cardin received her Ph.D. degree in Microbiology from Louisiana State University on the mechanisms of bacteriochlorophyll synthesis in a photosynthetic bacterium. She completed her postdoctoral studies on murine cytomegalovirus pathogenesis at Stanford University School of Medicine in 1994. She then joined the laboratory of Dr. Peter Doherty at St. Jude Children’s Research Hospital in Memphis, Tenn, USA, as an Instructor-Level Scientist to work on murine gammaherpesvirus pathogenesis and immunology as a model for the human gammaherpesviruses, EBV and KSHV. During her exciting time in Dr. Doherty’s laboratory, he was awarded the 1996 Nobel Prize in Medicine for his pioneering research in immunology. In 1998, she joined Park-Davis Pharmaceuticals as a Senior Scientist where she supervised the In Vivo Herpesvirus program for evaluation of anti-herpesvirus compounds in animal models. She also worked on the development of high-throughput assays for discovery of HIV entry inhibitors. After the Pfizer, Inc. merger with Parke-Davis, she joined ChemoCentryx, Inc. in the San Francisco Bay area as a Senior Scientist to work on chemokine therapeutics for diseases and vaccine strategies. In 2003, she joined the Division of Infectious Diseases at Cincinnati Children’s Hospital Medical Center as a Faculty Member. Her research efforts are aimed at characterizing host and viral genes required for CMV pathogenesis and latency. She is a Coinvestigator on an NIH contract for evaluating novel antivirals in CMV and HSV animal models and has received research funding from the American Heart Association and from industry contracts.
Biography Updated on 3 January 2011